

John T. Root, Jr.
ATTORNEY AT LAW
P.O. Box 701
Greenbrier, Arkansas 72058
Phone: (501) 529-8567
Fax: (501) 325-1130
j.root.5013@gmail.com

February 3, 2017

OTC Markets Group, Inc.
304 Hudson Street
Third Floor
New York, New York 10013

Our Client: Enerkon Solar International, Inc. (“ENKS”)¹, *fka* Castle Holding Corp. (“CHOD”)
Matter: Letter with Respect to Adequate Current Information & Disclosure

Ladies and Gentlemen:

In our capacity as special counsel to Castle Holding Corp., (“Issuer”) we have been requested to provide certain information and assurances in connection with Issuer’s posting of the issuer’s Annual (Financial) Report (as an SEC Form 10-K) on a website or websites maintained, administered or controlled by the OTC Markets Group, Inc. (“OTC”). The issuer posted the Annual Report (Form 10K) for the year ending September 30, 2017 on October 27, 2017, as well as Supplemental Information to the OTC Disclosure on both January 31, 2018.

This letter (the “Letter”) is provided to OTC with respect to adequate current information in regard to the securities issued by the Issuer (the “Securities”). We have acted as legal counsel to Issuer in connection with review of the posting of the information on the OTC News Service (www.otcmarkets.com). Our client is not requesting this Letter for the purpose of currently issuing securities, and seeks to make additional information available to the public with this Letter.

Pursuant to the requirement established by OTC, we hereby confirm the following, specifically subject to the following limitations, exceptions, qualifications, and assumptions:

1. OTC is entitled to rely on this letter in determining whether the Issuer has made current information publicly available within the meaning of Rule 11(c)(2) of the Securities Act of 1933 (the “Act”).
2. The undersigned is a United States resident and has been retained by Issuer for the purpose of rendering this letter and all matters address herein. This law firm serves as outside counsel to

¹ On November 1, 2017, the company received notification from FINRA that its application for a name change was accepted/approved and effective as of November 3, 2017.

Issuer. The undersigned is not and has not ever been a member of the Board of Directors of Issuer.

3. We have made such legal and factual examinations and inquiries as we have deemed advisable or necessary for the purpose of rendering this letter. In addition, we have examined, among other things, originals or copies of such corporate records and documents of Issuer, certificates of public officials, and such other documents and questions of law that we considered necessary, advisable, or appropriate for the purpose of rendering this letter.
4. The undersigned is a member of the Bar of the State of Arkansas. We express no opinion as to the laws of any jurisdiction other than corporate laws of the laws of the State of Nevada only where specifically referenced, as well as the federal laws of the United States of America. We express no opinion with respect to the effect or application of any other laws. Special rulings of authorities administering any of such laws of opinions of other counsel have not been sought or obtained by us in connection with rendering this letter.
5. The undersigned is permitted to practice before the United States Securities and Exchange Commission (the "SEC") and has not been prohibited from practice thereunder.
6. In conducting our examination in connection with the delivery of this Letter, as to matters of fact we have relied upon information obtained from public's officials, officers of Issuer, and other sources, we confirm that all such sources were believed to be reliable. We further assumed without investigation (i) the genuineness of all signatures on original documents; (ii) the authenticity and completeness of all documents submitted to use as originals; (iii) the conformity to original documents of all documents submitted to us as copies; (iv) the legal capacity of all natural personas executing any documents; (v) the due authorization, execution, and delivery of all documents on all parties other than Issuer; and, (vi) the truth, accuracy and completeness of the Information, factual matters, representations, and warranties contained in the information we received from public officials, officers of Issuer, and other sources.
7. The following documents have been reviewed by the undersigned in connection with the delivery of this letter (the "information"), in addition to those reviewed previously for the opinion letter regarding the financial information and disclosures of the company for fiscal year end September 30, 2017. The applicable date for this letter is deemed to be September 30, 2017. Except in instances of confidentiality or for items and issues of a proprietary nature, the information reviewed is publicly available through the OTC News Service with the date each respective document was posted on the OTC News Service noted below. This list does not include documents that are the subject of letters covering prior periods. Additional documents reviewed by the undersigned that may or may not be publicly available through the OTC News Services are listed as well. The information referenced includes as follows:

Letter to OTC Markets Group, Inc.

February 3, 2018

Page 3

Posted	Description	Effective
Jan 31, 2018	<u>Supplemental Information</u> - OTC Guideline Disclosure 12-31-3017	Dec 31, 2017
Jan 30, 2018	<u>Quarterly Report</u> - Quarterly Report - 10 Q Complete Financials and Mngement Discussion	Dec 31, 2017
Nov 8, 2017	<u>Supplemental Information</u> - 8 K Related to Corporate Name Change	Oct 31, 2017
Oct 27, 2017	<u>Annual Report</u> - Discussion and Corporate Financials	Sept 30, 2017
Aug 6, 2017	<u>Supplemental Information</u> - OTC Guideline Disclosure 6-3017	Jun 30, 2017
Aug 5, 2017	<u>Quarterly Report</u> - 10 Q Complete Financials and Mngement Discussion	Jun 30, 2017
Jul 17, 2017	<u>Officer/Director Disclosure</u> - Resignation of Michael Studer as Officer and Director	Jul 17, 2017
May 3, 2017	<u>Supplemental Information</u> - OTC Disclosure for 3-31-17	Mar 31, 2017
May 2, 2017	<u>Quarterly Report</u> - Complete Financials and Management Disscusion	Mar 31, 2017
Feb 13, 2017	<u>Attorney Letter with Respect to Current Information</u> - Adequate Disclure Letter	Sept 30, 2016
Feb 1, 2017	<u>Supplemental Information</u> - OTC Disclosure for 12-31-16	Dec 31, 2016
Jan 24, 2017	<u>Quarterly Report</u> - 10 Q- Management Discussion and Complete Financials	Dec 31, 2016
Jan 4, 2017	<u>Supplemental Information</u> - OTC Disclosure 9-3-16	Sept 30, 2016
Nov 3, 2016	<u>Annual Report</u> - Discussion and Complete Financials	Sept 30, 2016
Aug 18, 2016	<u>Supplemental Information</u> - OTC Disclosure 6-30-16	Jun 30, 2016
Jul 29, 2016	<u>Research Report</u> - OTC Basic Disclosure Quarter Ending 6-30-16	Jun 30, 2016
Jul 21, 2016	<u>Quarterly Report</u> - 10 Q 6-30-16 Mgmt. Discussion and Complete Financials	Jun 30, 2016
May 2, 2016	<u>Attorney Letter with Respect to Current Information</u> - Adequate Disclosure Letter 5-2-16	Mar 31, 2016
Apr 28, 2016	<u>Semi-Annual Report</u> - 10 Q 3-31-16 Mgmt. Discussion and Complete Financials	Mar 31, 2016

8. To our knowledge, the Information as of the date covered by Issuer's various disclosure and filings: (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144 (c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act") with the exception of financial statements for the Issuer for the two preceding fiscal years; (iii) complies as to form with the OTC Guidelines for Providing Adequate Current Information; and, (iv) has been posted in the OTC News Service.

9. With regard to the Financial Statements contained in and constituting part of the information:

The person responsible for the preparation for the Financial Statement was John Capello. Dr. Cappello has over 40 years industrial and business experience. He has extensive background in corporate capacities with Rohm & Haas and PQ Industries. He has been active in all stages of product development as a synthesis chemist, applications chemistry, market development and product management. In addition, he is highly experienced in Corporate Development (specializing in innovative products, including pharmaceutical and medical). He also spearheaded Harbor Medical and numerous other successful medical practice and related businesses. In addition, he was successfully involved in prior public company endeavors. He is currently President and CEO of Cappellos, Inc., a private Research and Development Company, and also former President and CEO of Emergent Health Corp, a non-reporting public company which he developed to over \$5,000,000 in cumulative sales and sold control in August 2014.

- (a) As noted above, the Chief Executive Officer (John Cappello) is qualified to prepare the financials.
- (b) The Financials are not audited at this time.
- (c) The Issuer has no listed accounting provider and has no current need for one.

10. With regard to Issuer's transfer agent:

- (a) Issuer's transferred agent is Standard Registrar & Transfer Company and Transfer Company, Inc., 12528 South 1840 East, Draper, UT 84020;
- (b) Issuer's transfer agent is registered with the SEC.
- (c) In confirming the number of outstanding shares set forth in the Information, the undersigned relied upon data provided directly by the Issuer's transfer agent with respect to shareholders of record and total shares issued by reviewing a shareholder's listing produced by the transfer agent and the information as stated in the posted information described in Paragraph 7, *above*.

11. The undersigned hereby confirms that the undersigned has undertaken of the following in connection with the delivery of this Letter: (i) personally met the management and directors of the Issuer; (ii) reviewed the Information, as amended, published by the Issuer on the OTC News

Service; and, (iii) discussed the Information with Management and a majority of the directors of the Issuer.

12. To the best knowledge of the undersigned, after inquiry of management and the directors of the Issuer, as of the date covered by the Initial Disclosure Statement neither (i) the Issuer of the Securities; (ii) any five percent (5%) holder; nor, (iii) counsel to the Issuer was under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

Parties owning in excess of % 5 of the shares include:

- John Cappellos
- Cappellos, Inc.
- Castle Holding Corp. Deferred Compensation Plan *fbo* George Herbert

13. This opinion is rendered solely to OTC for its benefit as of the date of this Letter, though it applies to all facts and circumstances as of September 30, 2017. As such, it may not be relied upon by any other person without our prior written consent, and may not be used for any other purpose. However, OTC is granted full and complete permission and right to publish a copy of this letter in the OTC news Service for viewing by the public and regulators.

14. The following is a list, and a pertinent information for each respective person, of each (i) executive officer, directors, general partner, and other control person of the Issuer; and, (ii) promoter, finder, consultant, or any other advisor of the Issuer that assisted, prepared, or provided information with respect to the Issuer's disclosure or who received securities as consideration for services rendered to the Issuer:

- (a) John Cappello: C.E.O. of Issuer, as well as being an experienced project development manager and marketer and leader of a \$5 million in sales self-named marketing firm;
- (b) George R. Herbert: President.
- (c) Teresa M. Hebert, wife of George R. Hebert, has been a director of Castle Holding Corp. since November 2003.

15. The undersigned hereby confirms that he has made specific inquiry of (i) each of these persons listed in Paragraph 14, above; (ii) persons engaged in promotional activities regarding the issuer; and, (iii) persons owning more than ten percent (10%) of the Securities (collectively, the "Insiders"), and based upon such inquiries and other information available to the undersigned, confirms that the client is not requesting this letter for the purpose of currently issuing securities and seeks to make additional information available to the public with this Letter. Further, based upon such inquiries and other information available to the undersigned, any sales of Securities by Insiders within the twelve-month period prior to this letter have been made in compliance with

Rule 144, including, without limitation, any required filings of Form 144, and nothing has come to the attention of the undersigned indication that any of the Insiders is in possession of any material non-public information regarding the Issuer or Securities that would prohibit any of them from buying or selling Securities at the time this letter has been composed and executed under Rules 10b-5 or 10b5-1 under the Exchange Act.

As used in this Letter, the expression "to our knowledge" refers to the current actual knowledge of the attorneys of this firm who have worked on matter for Issuer (whether or not solely in connection with the delivery of this Letter or the preparation of the Information), and without any independent investigation of any underlying facts or situations. This Letter is expressly limited to the matter expressly stated herein and no other opinions are implied by, or are to be inferred from, this letter. Without limiting the prior sentence, we express no opinion as to any documents or matters except the Information as provided for herein. This Letter is further limited to questions arising under the law of the State of Nevada (where identified), and the federal laws of the United States of America (where identified). Accordingly, we express no opinion as to matters governed by the law of any other jurisdiction. This letter is based upon the law in effect on the date hereof, and we assume no obligation to revise or supplement it should such a law be changed by the legislative action, judicial decision, or otherwise. We further disclaim any obligation to update this Letter or to advise OTC or anyone else of facts, circumstances, events, or developments which hereafter may be brought to our attention and which may alter, affect, or modify this Letter.

On behalf of the Issuer, we appreciate your assistance. Please feel free to contact the undersigned should you have any comments or questions in regard to the information or any of the matters addressed herein.

Sincerely,

A handwritten signature in cursive script that reads "John T. Root, Jr." The signature is written in dark ink and is positioned above the printed name.

John T. Root, Jr., Esq.